Product Description
SAM-760 is a potent and selective 5-HT6receptor antagonist that has demonstrated central 5-HT6receptor saturation in humans at a dose of 30 mg.
Mechanisms of Action: 5-HT6 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Alzheimer Disease
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| B2081011 | P2 |
Terminated |
Alzheimer Disease |
2015-09-01 |
|
| B2081007 | P1 |
Completed |
Healthy Volunteers |
2011-05-01 |
|
| 3276A1-1000 | P1 |
Completed |
Healthy Volunteers |
2010-12-01 |
|
| MAD | P1 |
Completed |
Healthy Volunteers |
2010-12-01 |